The rosiglitazone meta-analysis

Reviews in Cardiovascular Medicine

Volumn 8, Issue 2, 2007, Pages 123-126

  McCullough, Peter A ^a   Lepor, Norman E ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DEATH; DIABETES MELLITUS; DRUG SAFETY; EDEMA; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; META ANALYSIS; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS; MYOCARDIAL INFARCTION; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 34447259099     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:1-15.
2. Hughes S. The rosiglitazone aftermath: legitimate concerns or hype? Available at: http://www.medscape.com/viewarticle/557198. Accessed May 29, 2007.
3. Epi-Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and Prevention; 1993.
4. Use of oral hypoglycemic agents. Available at: http://intl. elsevierhealth.com/e-books/viewbook.cfm?ID=967. Accessed May 29, 2007.
5. The DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105.
6. Kahn SE, Haffner SM, Heise MA, et al, on behalf of the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
7. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 2007;357. E-pub ahead of print.